Status:
COMPLETED
Cognition, Functioning and Quality of Life
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborating Sponsors:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
People affected by schizophrenia often experience poor concentration, lapses in memory and difficulty with completing tasks; and this set of problems are known as neuro-cognitive deficits. Traditional...
Detailed Description
Schizophrenia is a chronic, debilitating psychiatric disorder with complex clinical presentation, partially responsiveness to treatment and varied outcomes. Though modern anti-psychotic drugs have bee...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia confirmed by administering SCID and,
- Subjects consecutively referred for optimizing antipsychotic drug therapy, i.e. a change of medication from conventional medications or Risperidone is indicated due to lack of efficacy, side-effects or poor subjective tolerability.
- Competent to provide an informed consent.
Exclusion
- Substance dependence, mental retardation, head injury or other primary neurological disorders.
- Imminent risk due to suicidal or aggressive behavior (a score of five or more on the hostility item on the PANSS).
- A pattern of social instability, which could hamper long-term follow-up.
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00182442
Start Date
October 1 2003
End Date
March 1 2006
Last Update
October 11 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McMaster University
Hamilton, Ontario, Canada